Searchable abstracts of presentations at key conferences in endocrinology

ea0035p918 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Pharmacokinetic (PK) and pharmacodynamic (PD) analyses of pasireotide LAR and octreotide LAR: Randomized, double-blind Phase III study in patients with medically naive acromegaly

Shen George , Darstein Christelle , Resendiz Karina Hermosillo , Wang Yanfeng , Hu Ke

Introduction: A recent 12-month randomized, double-blind study showed that pasireotide LAR was superior to octreotide LAR at providing biochemical control (GH and IGF1) in medically naïve patients with acromegaly. This analysis evaluates the PK/PD of pasireotide and octreotide in these patients.Methods: Patients received pasireotide LAR 40 mg/28 day (n=176) or octreotide LAR 20 mg/28 day (n=182) for 12 m. The relationship between p...